compound 72 [WO2013026806]   Click here for help

GtoPdb Ligand ID: 8166

Synonyms: compound 8c [PMID 25264830] [3] | EHT 5372 [1]
Compound class: Synthetic organic
Comment: This is compound 72, an invention covered by patent WO2013026806 [5]. Compound 72 is a highly potent dual DYRK1A/1B inhibitor (DYRK = dual-specificity tyrosine-regulated kinase).
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 6
Hydrogen bond donors 2
Rotatable bonds 4
Topological polar surface area 112.02
Molecular weight 369.05
XLogP 3.53
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES COC(=N)c1nc2c(s1)c1c(ncnc1cc2)Nc1ccc(cc1)Cl
Isomeric SMILES COC(=N)c1nc2c(s1)c1c(ncnc1cc2)Nc1ccc(cc1)Cl
InChI InChI=1S/C17H12ClN5OS/c1-24-15(19)17-23-12-7-6-11-13(14(12)25-17)16(21-8-20-11)22-10-4-2-9(18)3-5-10/h2-8,19H,1H3,(H,20,21,22)
InChI Key BGXZIBSLBRKDTP-UHFFFAOYSA-N
No information available.
Mechanism Of Action and Pharmacodynamic Effects Click here for help
Compound 72 was developed primarily for its potential to modulate the enhanced activity of DYRK1A in Down's syndrome-related Alzheimer's disease. Additional uses covered by the patent include treatment of other neurodegenerative conditions and some cancers (specifically certain solid tumours) [5].
The DYRK1A gene is located within the Down Syndrome (DS) critical region on chromosome 21. Trisomy of chromosome 21 leads to overexpression of DYRK1A and amyloid precursor protein (APP), and this may underlie the Tau and amyloid pathologies associated with early onset Alzheimer's disease in DS [2,4,6-7]. Pharmacological inhibition of DYRK1A activity would aim to modify the course of AD pathogenesis.